The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of the study as planned. The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. There has been no safety...
Hence then, the article about foresee pharmaceuticals receives the fourth positive recommendation from the dsmb to continue the casppian ph3 study for central precocious puberty cpp was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP) )
Also on site :
- California Dreamin’: NBC Kicks Off 2028 L.A. Olympics Marketing Campaign With Kate Hudson (Exclusive)
- Zelensky tells BBC Putin has started WW3 and must be stopped
- Not all degrees are a waste of time: MBA graduates from Harvard, MIT, and Wharton are making over $245,000 just three years after graduating